• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Acute hepatic porphyrias: Current diagnosis & management.急性肝卟啉症:当前的诊断与管理。
Mol Genet Metab. 2019 Nov;128(3):219-227. doi: 10.1016/j.ymgme.2019.07.002. Epub 2019 Jul 5.
2
AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.AGA 临床实践更新:急性肝性血卟啉症的诊断和管理:专家综述。
Gastroenterology. 2023 Mar;164(3):484-491. doi: 10.1053/j.gastro.2022.11.034. Epub 2023 Jan 13.
3
Acute hepatic porphyrias: Recommendations for diagnosis and management with real-world examples.急性肝卟啉病:诊断与管理建议及实际案例
Mol Genet Metab. 2023 Nov;140(3):107670. doi: 10.1016/j.ymgme.2023.107670. Epub 2023 Jul 27.
4
Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).急性肝性卟啉症(AHPs)的发病机制和临床特征。
Mol Genet Metab. 2019 Nov;128(3):213-218. doi: 10.1016/j.ymgme.2019.03.002. Epub 2019 Mar 6.
5
5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.δ-氨基酮戊酸脱水酶卟啉症:肝 5-氨基酮戊酸合酶诱导的最新进展及对血红素的长期反应
Mol Genet Metab. 2020 Dec;131(4):418-423. doi: 10.1016/j.ymgme.2020.10.011. Epub 2020 Oct 26.
6
Hepatic porphyria: A narrative review.肝性卟啉病:一篇叙述性综述。
Indian J Gastroenterol. 2016 Nov;35(6):405-418. doi: 10.1007/s12664-016-0698-0. Epub 2016 Oct 31.
7
Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.急性肝卟啉症的诊断和治疗挑战:从罕见的儿科发病到创新治疗和前景。
Orphanet J Rare Dis. 2022 Apr 7;17(1):160. doi: 10.1186/s13023-022-02314-9.
8
Canadian guidance for diagnosis and management of acute hepatic porphyrias.加拿大急性肝卟啉症诊断和管理指南。
Clin Biochem. 2024 Oct;131-132:110792. doi: 10.1016/j.clinbiochem.2024.110792. Epub 2024 Jul 9.
9
Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments.急性肝性和红细胞生成性卟啉病:从δ-氨基-γ-酮戊酸合酶1和2到新的分子基础与治疗方法
Curr Opin Hematol. 2017 May;24(3):198-207. doi: 10.1097/MOH.0000000000000330.
10
Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.急性肝性血卟啉症患者的疾病负担:来自 3 期 ENVISION 研究的经验。
Orphanet J Rare Dis. 2022 Aug 26;17(1):327. doi: 10.1186/s13023-022-02463-x.

引用本文的文献

1
siRNA Therapeutics for the Treatment of Hereditary Diseases and Other Conditions: A Review.用于治疗遗传性疾病和其他病症的小干扰RNA疗法:综述
Int J Mol Sci. 2025 Sep 5;26(17):8651. doi: 10.3390/ijms26178651.
2
An easily overlooked disease in the early stages: acute intermittent porphyria.一种在早期容易被忽视的疾病:急性间歇性卟啉病。
BMC Neurol. 2025 Feb 13;25(1):61. doi: 10.1186/s12883-025-04064-0.
3
Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study.一项定性访谈研究中急性肝卟啉症患者在长期使用吉沃赛安治疗前后的体验
Mol Genet Metab Rep. 2024 Dec 20;42:101174. doi: 10.1016/j.ymgmr.2024.101174. eCollection 2025 Mar.
4
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.急性间歇性血卟啉症患者在一项 1/2 期、48 个月开放标签扩展研究中的吉沃西仑长期治疗随访结果。
Orphanet J Rare Dis. 2024 Oct 3;19(1):365. doi: 10.1186/s13023-024-03284-w.
5
The Growing Class of Novel RNAi Therapeutics.新型 RNAi 治疗药物不断增加。
Mol Pharmacol. 2024 Jun 18;106(1):13-20. doi: 10.1124/molpharm.124.000895.
6
Hereditary Coproporphyria in Which the Patient's Course Improved after the Discontinuation of Givosiran.经戈昔瑞林停药后病情改善的遗传性粪卟啉症
Intern Med. 2024 Nov 1;63(21):2961-2964. doi: 10.2169/internalmedicine.3284-23. Epub 2024 Mar 11.
7
Liver transplantation and primary liver cancer in porphyria.肝移植与卟啉病中的原发性肝癌
Liver Int. 2025 Mar;45(3):e15894. doi: 10.1111/liv.15894. Epub 2024 Mar 8.
8
The diagnosis of acute intermittent porphyria combined with seizures: Case report.急性间歇性血卟啉病合并癫痫发作的诊断:病例报告。
Medicine (Baltimore). 2023 Dec 15;102(50):e36167. doi: 10.1097/MD.0000000000036167.
9
Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study.日本急性肝性卟啉症患者急性发作、慢性症状和长期并发症的临床特征:一项真实世界理赔数据库研究。
Orphanet J Rare Dis. 2023 Dec 8;18(1):384. doi: 10.1186/s13023-023-02913-0.
10
A high urinary urobilinogen/serum total bilirubin ratio indicates acute hepatic porphyria in patients with abdominal pain.尿胆原/血清总胆红素比值高提示腹痛患者发生急性肝卟啉症。
Sci Rep. 2023 Dec 4;13(1):21330. doi: 10.1038/s41598-023-48824-9.

本文引用的文献

1
Clinical Remission of Delta-Aminolevulinic Acid Dehydratase Deficiency Through Suppression of Erythroid Heme Synthesis.通过抑制红系血红素合成实现δ-氨基乙酰丙酸脱水酶缺乏症的临床缓解
Hepatology. 2019 Jul;70(1):434-436. doi: 10.1002/hep.30543. Epub 2019 Jun 6.
2
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.系统信使 RNA 作为急性间歇性卟啉症的病因治疗方法。
Nat Med. 2018 Dec;24(12):1899-1909. doi: 10.1038/s41591-018-0199-z. Epub 2018 Oct 8.
3
Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.生物工程化 PBGD 变体提高急性间歇性卟啉症基因治疗载体的治疗指数。
Hum Mol Genet. 2018 Nov 1;27(21):3688-3696. doi: 10.1093/hmg/ddy283.
4
Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.反复发作的急性肝性卟啉症:肝脏慢性炎症反应的主要作用。
J Intern Med. 2018 Jul;284(1):78-91. doi: 10.1111/joim.12750. Epub 2018 Mar 26.
5
An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria.可响应不同卟啉生成刺激的诱导型启动子可改善急性间歇性卟啉症的基因治疗载体。
Hum Gene Ther. 2018 Apr;29(4):480-491. doi: 10.1089/hum.2017.056. Epub 2018 Jan 2.
6
Acute hepatic porphyrias: Recommendations for evaluation and long-term management.急性肝卟啉病:评估与长期管理建议
Hepatology. 2017 Oct;66(4):1314-1322. doi: 10.1002/hep.29313. Epub 2017 Sep 4.
7
An Audit of the Use of Gonadorelin Analogues to Prevent Recurrent Acute Symptoms in Patients with Acute Porphyria in the United Kingdom.英国使用促性腺激素释放激素类似物预防急性卟啉病患者复发性急性症状的审计
JIMD Rep. 2017;36:99-107. doi: 10.1007/8904_2017_2. Epub 2017 Feb 21.
8
Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments.急性肝性和红细胞生成性卟啉病:从δ-氨基-γ-酮戊酸合酶1和2到新的分子基础与治疗方法
Curr Opin Hematol. 2017 May;24(3):198-207. doi: 10.1097/MOH.0000000000000330.
9
A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease.肽转运体2的一种变体可预测卟啉症相关肾病的严重程度。
J Am Soc Nephrol. 2017 Jun;28(6):1924-1932. doi: 10.1681/ASN.2016080918. Epub 2016 Dec 28.
10
Update review of the acute porphyrias.急性卟啉症更新综述。
Br J Haematol. 2017 Feb;176(4):527-538. doi: 10.1111/bjh.14459. Epub 2016 Dec 16.

急性肝卟啉症:当前的诊断与管理。

Acute hepatic porphyrias: Current diagnosis & management.

机构信息

The University of Texas Medical Branch, Department of Preventive Medicine and Community Health and Internal Medicine, 301 University Boulevard, Galveston, TX 77555-1109, United States of America.

出版信息

Mol Genet Metab. 2019 Nov;128(3):219-227. doi: 10.1016/j.ymgme.2019.07.002. Epub 2019 Jul 5.

DOI:10.1016/j.ymgme.2019.07.002
PMID:31311713
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6911835/
Abstract

Each of the four acute hepatic porphyrias is due to mutation of an enzyme in the heme biosynthetic pathway. The accumulation of pathway intermediates that occur most notably when these diseases are active is the basis for screening and establishing a biochemical diagnosis of these rare disorders. Measurement of enzyme activities and especially DNA testing also are important for diagnosis. Suspicion of the diagnosis and specific testing, particularly measurement of urinary porphobilinogen, are often delayed because the symptoms are nonspecific, even when severe. Urinary porphyrins are also measured, but their elevation is much less specific. If porphobilinogen is elevated, second line testing will establish the type of acute porphyria. DNA testing identifies the familial mutation and enables screening of family members. Management includes removal of triggering factors whenever possible. Intravenous hemin is the most effective treatment for acute attacks. Carbohydrate loading is sometimes used for mild attacks. Cyclic attacks, if frequent, can be prevented by a GnRH analogue. Frequent noncyclic attacks are sometime preventable by scheduled (e.g. weekly) hemin infusions. Long term complications may include chronic pain, renal impairment and liver cancer. Other treatments, including RNA interference, are under development.

摘要

四种急性肝卟啉症均由血红素生物合成途径中酶的突变引起。当这些疾病活跃时,途径中间产物的积累是筛查和建立这些罕见疾病生化诊断的基础。酶活性的测量,尤其是 DNA 检测,对诊断也很重要。由于症状不具特异性,甚至在严重情况下,这些疾病的诊断和具体检测(尤其是尿卟胆原的测量)常常被延迟。尿卟啉也被测量,但它们的升高特异性较差。如果卟胆原升高,则二线检测将确定急性卟啉症的类型。DNA 检测可识别家族突变,并能对家庭成员进行筛查。管理包括尽可能去除触发因素。静脉内血红素是急性发作最有效的治疗方法。碳水化合物负荷有时用于轻度发作。如果发作频繁,可以使用 GnRH 类似物预防周期性发作。如果经常非周期性发作,可以通过定期(例如每周)血红素输注来预防。长期并发症可能包括慢性疼痛、肾功能损害和肝癌。其他治疗方法,包括 RNA 干扰,正在开发中。